OmniAb, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Brendan Smith from TD Cowen maintained a Buy rating on the stock and has a $4.00 price target.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Brendan Smith has given his Buy rating due to a combination of factors that highlight OmniAb’s strategic positioning and operational improvements. The company has made significant progress in streamlining its operations, as evidenced by a notable reduction in operating expenses, particularly in research and development. This cost-saving initiative is part of a broader effort to enhance efficiency and reduce cash burn, which is expected to position the company favorably for long-term growth.
Furthermore, OmniAb’s introduction of the xPloration product, which leverages AI and machine learning, represents a promising expansion of its technology platform. This innovation is anticipated to open new revenue streams as it gains traction among partners. Additionally, while revenue from drug discovery remains inconsistent, the company is poised to benefit from potential royalties from partner program approvals, which could further bolster its financial outlook. These elements collectively underpin Smith’s optimistic view of OmniAb’s future prospects.
Based on the recent corporate insider activity of 29 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of OABI in relation to earlier this year.